Reckitt: share price rises despite lackluster 2024 results

(CercleFinance.com) - British FMCG group Reckitt reported lackluster 2024 full-year results on Thursday, but the prospect of accelerating organic growth this year and simplifying the business seemed to please the market.


The owner of Strepsils lozenges, Nurofen painkiller and Durex condoms, among others, announced this morning that it had achieved organic sales growth of 1.4% in 2024, against a consensus of 1.6%.

Operating profit rose by 3% to £3.47 billion, corresponding to an operating margin of 24.5%, an improvement of 1.5 percentage points on 2023.

Under the leadership of its new CEO, Kris Licht, Reckitt is attempting to restructure itself into a more efficient company focused on 11 strong brands ('powerbrands') and centered on the health and hygiene markets.

On the basis of this core perimeter, the company says it is targeting organic sales growth of 2% to 4% this year, while organic growth at group level is expected to be between 2% and 4%.

Following this publication, the share gained 2.8% on Thursday morning on the London Stock Exchange, posting one of the best performances of the FTSE 100 index.

Copyright (c) 2025 CercleFinance.com. All rights reserved.